Biolinq Shine™ Granted De Novo Classification by U.S. FDA for the First Fully Autonomous, Needle-Free Glucose Sensor

First glucose sensor with an integrated primary display that works with and without a phone Establishes a new category of wearable glucose sensors for metabolic health

Written by

Cammy Duong

Sofia Bermudez

Recent news

Tech Innovators Weekly

April 4, 2024

Biolinq Secures $58M to Power Next-Gen Glucose Monitoring Platform

Biolinq raked in $58 million in capital this week. The company is developing a wearable patch that uses electrochemical sensors to measure a person’s glucose levels from the intradermal space just beneath the surface of their skin.

Wall Street Journal: Investors Put $58 Million Into Biolinq’s Push for Novel Glucose-Monitoring

Startup seeks to help people with Type 2 diabetes via a device that uses microneedles to measure blood sugar and doesn’t require a separate device to deliver its results.

Biolinq Shine™ Granted De Novo Classification by U.S. FDA for the First Fully Autonomous, Needle-Free Glucose Sensor

First glucose sensor with an integrated primary display that works with and without a phone Establishes a new category of wearable glucose sensors for metabolic health

Written by

Sofia Bermudez

Medical Device Network

April 4, 2024

Biolinq raises $58m for glucose microsensor pivotal trial

Biolinq is eying an FDA application this year, according to CEO Richard Yang. “The pivotal study started in March 2024 and we plan to file for US Food and Drug Administration (FDA) clearance this year.” said Yang.

Biolinq lands $58m to advance wearable metabolic health technology

Health tech company Biolinq has secured $58 million in new funding to advance its biosensor technology for enhancing metabolic health. Company targets clinical trial of groundbreaking CGM device that detects blood glucose levels just below the surface of the skin.

Written by

Danny Sullivan

Modern Living Quarterly

April 4, 2024

Biolinq Raises $58M for Color-Coded Wearable Glucose Sensor

The “barely there” wearable touts a color-changing interface for quick glucose insights without the need for a secondary device. Health tech companies zeroing in on metabolic health advancements continue to score investors as they look to make it easier than ever for consumers to assess metabolic insights.

Written by

Courtney Rehfeldt

San Diego Business Journal

May 9, 2024

Biolinq Raises $58m

BIOTECH: Advancing Ultra-Small Biosensors for Diabetes. The company's burgeoning success has the potential to shake up a glucose monitoring market that's dominated by heave hitters like Dexcom and Abbott.

Biolinq raises $58M for wearable biosensor tech

California-based Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it scored $58 million in financing.

Biolinq raises $58M to support intradermal glucose sensor

Biolinq announced today that it completed $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated.

Written by

Sean Whooley

The Financial Gazette

April 4, 2024

Biolinq Raises $58 Million Through Pivotal Trial

Biosensor platform leverages silicon semiconductor manufacturing for scale. Technology designed to provide a better view of metabolic health by combining glucose information with context around activities of daily living in one device. $58 million in funding led by Alpha Wave Ventures.

Biolinq: Less pain, $58m gain for tiny glucose sensor

In a sweet indication of an improving capital market for med-tech companies, Biolinq Inc. landed $58 million in bridge financing to support completion of the U.S. pivotal trial of its intradermal glucose sensor and submission to the U.S. FDA.

Biolinq Announces Close of $100M Series C Financing to Advance Its Biowearable Platform for Metabolic Health

The Series C funding supports Biolinq’s transition from development stage to commercial readiness following US pivotal trial completion and regulatory submission.

Written by

Kimberly Ha

The Arts Review Digest

April 12, 2023

Digital Health C-Suite Series: Biolinq CEO Rich Yang

We had the pleasure of speaking with Biolinq CEO Rich Yang during the annual JP Morgan healthcare conference about developing the world’s first sensor to detect glucose levels in the skin, supporting sustainable behavior changes and the challenge of developing a digital platform.

Written by

Jamie Burgess

Biolinq Shine™ Granted De Novo Classification by U.S. FDA for the First Fully Autonomous, Needle-Free Glucose Sensor

Recent news

Biolinq Secures $58M to Power Next-Gen Glucose Monitoring Platform

Wall Street Journal: Investors Put $58 Million Into Biolinq’s Push for Novel Glucose-Monitoring

Biolinq Shine™ Granted De Novo Classification by U.S. FDA for the First Fully Autonomous, Needle-Free Glucose Sensor

Biolinq raises $58m for glucose microsensor pivotal trial

Biolinq lands $58m to advance wearable metabolic health technology

Biolinq Raises $58M for Color-Coded Wearable Glucose Sensor

Biolinq Raises $58m

Biolinq raises $58M for wearable biosensor tech

Biolinq raises $58M to support intradermal glucose sensor

Biolinq Raises $58 Million Through Pivotal Trial

Biolinq: Less pain, $58m gain for tiny glucose sensor

Biolinq Announces Close of $100M Series C Financing to Advance Its Biowearable Platform for Metabolic Health

Digital Health C-Suite Series: Biolinq CEO Rich Yang

About Biolinq

Media Contact